This guidance has been updated and replaced by NICE technology appraisal guidance on dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134).
This guidance has been updated and replaced by NICE technology appraisal guidance on dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134).